Connor, Clark & Lunn Investment Management (CC&L)’s PDL BioPharma, Inc. PDLI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,167,755	Closed	-$6.83M	–	1094
2020 Q3	$6.83M	Sell	2,167,755 -803,221	-27%	-$2.57M	0.05%	255
2020 Q2	$8.65M	Sell	2,970,976 -764,710	-20%	-$2.42M	0.06%	221
2020 Q1	$10.5M	Sell	3,735,686 -271,650	-7%	-$876K	0.09%	150
2019 Q4	$13M	Sell	4,007,336 -379,702	-9%	-$1.1M	0.09%	160
2019 Q3	$9.48M	Sell	4,387,038 -100,546	-2%	-$269K	0.07%	181
2019 Q2	$14.1M	Sell	4,487,584 -503,889	-10%	-$1.63M	0.09%	159
2019 Q1	$18.6M	Sell	4,991,473 -899,178	-15%	-$3.04M	0.12%	131
2018 Q4	$17.1M	Sell	5,890,651 -77,454	-1%	-$213K	0.12%	133
2018 Q3	$15.7M	Buy	5,968,105 +290,458	+5%	+$713K	0.09%	160
2018 Q2	$13.3M	Buy	5,677,647 +887,945	+19%	+$2.48M	0.07%	185
2018 Q1	$14.1M	Buy	4,789,702 +1,143,153	+31%	+$3.12M	0.09%	165
2017 Q4	$9.99M	Buy	3,646,549 +1,032,437	+39%	+$3.17M	0.06%	204
2017 Q3	$8.86M	Buy	2,614,112 +1,126,399	+76%	+$3.13M	0.05%	222
2017 Q2	$3.67M	Buy	1,487,713 +88,765	+6%	+$204K	0.02%	304
2017 Q1	$3.18M	Buy	1,398,948 +40,073	+3%	+$88.6K	0.02%	317
2016 Q4	$2.88M	Sell	1,358,875 -36,200	-3%	-$101K	0.02%	325
2016 Q3	$4.67M	Sell	1,395,075 -21,800	-2%	-$69.2K	0.03%	254
2016 Q2	$4.45M	Buy	1,416,875 +3,200	+0.2%	+$10.7K	0.03%	254
2016 Q1	$4.71M	Buy	1,413,675 +22,000	+2%	+$68.6K	0.04%	234
2015 Q4	$4.93M	Buy	1,391,675 +315,525	+29%	+$1.32M	0.04%	211
2015 Q3	$5.41M	Buy	1,076,150 +901,050	+515%	+$5.16M	0.04%	190
2015 Q2	$1.13M	Buy	+175,100	New	+$1.17M	0.01%	318
2014 Q3	–	Sell	-98,340	Closed	-$1.01M	–	625
2014 Q2	$1.01M	Buy	+98,340	New	+$876K	0.01%	321
2014 Q1	–	Sell	-112,434	Closed	-$1.01M	–	849
2013 Q4	$1.01M	Sell	112,434 -113,261	-50%	-$954K	0.01%	367
2013 Q3	$1.85M	Sell	225,695 -98,000	-30%	-$788K	0.02%	206
2013 Q2	$2.64M	Buy	+323,695	New	+$2.52M	0.03%	167

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PDLI Position: Q4 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 2,167,755 shares — an estimated $6.83M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PDLI in Q2 2013 and held it in 26 quarters. The position peaked at $18.6M in Q1 2019. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 2,167,755 PDL BioPharma, Inc. shares in Q4 2020, an estimated $6.83M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 26 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s PDL BioPharma, Inc. position peaked at $18.6M in Q1 2019.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2020, filed 16 Feb 2021.